Similar to our findings in patient 7 and 8, Lütje et al. evaluated six patients with iodine-negative metastatic differentiated thyroid carcinoma and found FDG-negative and PSMA-positive metastases in one patient, so we must emphasize at this point that we can expect to identify more of such patients in larger patient collectives, who may benefit from 68Ga-PMSA-PET/CT in terms of staging [31]. This evidence concerns the gene FOLH1 and differentiated thyroid carcinoma.